GLP-1(736)amide, GIP(142), and exendin-4, or liraglutide, and a low dose of vidagliptin (to prevent incretins degradation) were added to the human peripheral mononuclear cells cultures and incubated for a week
FIGURE 4 Glucagon-like peptide-1 receptor agonist-related other neoplasms Supplementary Figure S6 and Figure 5 demonstrate that the lower limit of PRR for GLP-1RA-associated bile duct cancer was greater than 1 in the first three models but less than 1 in model 4 (PRR 1.42, 95% CI 0.962.10, p = 0.03) and model 5 (PRR 1.39, 95% CI 0.952.03, p = 0.09)
PMID: 34668947, PMCID: PMC8529414, DOI: 10.1001/jamanetworkopen.2021.28182
Proactive hydration strategies can help patients taking GLP-1 receptor agonists maintain adequate fluid balance and minimize thirst-related discomfort
The only side effect is possible injection site irritation